91 filings
Page 4 of 5
8-K
e3moe55xkjm35l 2ys
3 Nov 15
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
u5ckvb
7 Aug 15
Departure of Directors or Certain Officers
12:00am
8-K
sdqgmmam91cw
27 Apr 15
Departure of Directors or Certain Officers
12:00am
8-K
o28 er9vpi61
31 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
l7ti5
29 Dec 14
Departure of Directors or Certain Officers
12:00am
8-K
bn9me914nh3s909fe
24 Oct 14
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
12:00am
8-K
8q01o
24 Sep 14
Cellceutix Provides Update to Shareholders
12:00am
8-K
6eftxt4xcj13309vi
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
8-K
vexvols0xewsq vn1z6c
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
8-K
mxho1oow3px4
9 Sep 13
Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
12:00am
8-K
9dn69zqj6 tim
5 Jun 13
Changes in Registrant's Certifying Accountant
12:00am
8-K
37ud2g3m0i ynro
8 Mar 13
Unregistered Sales of Equity Securities
12:00am
8-K
x6zyfdt ttoa
4 Mar 13
Cellceutix Signs with Leading Cancer Center For Licensing New Drug
12:00am
8-K
uioafh22ga w6
8 Jan 13
Termination of a Material Definitive Agreement
12:00am
8-K
u83 6ss8nlcg03
27 Dec 12
Regulation FD Disclosure
12:00am
8-K
ulyrpckuwn2votup
26 Dec 12
Cellceutix Comments on New York Times Article Heralding p53 Drugs as the New Age in Cancer Research
12:00am
8-K
qzrl0
10 Dec 12
Entry into a Material Definitive Agreement
12:00am
8-K
u5l8fpqd8qlcuov
29 Jun 12
Unregistered Sales of Equity Securities
12:00am
8-K
q20lo
22 Jun 12
Cellceutix Approved By FDA to Proceed with Clinical Trials on Novel Cancer Drug
12:00am
8-K
k1hq3dk
10 May 12
Unregistered Sales of Equity Securities
12:00am